Roche stocks have seen significant fluctuation due to various factors. Concerns over side effects in
obesity pill trials have led to a slump in shares. The company's Wegovy challenger caused patients to experience vomiting, further leading to a fall in stock prices. However, positive data for its obesity drugs rekindled investor interest, which got further boost as Tempest Therapeutics retained its Buy rating post Roche deal. Some good news for Roche included the potential benefit from Accu-Chek Smartguide Launch in Europe and early trial success of their second obesity drug candidate. Despite this,
Roche's shares took a hit due to a disappointing 2024 fiscal outlook and concerns about side effects from their flagship obesity drug. Morgan Stanley, however, retained a bullish stance on the European AI stock. Roche also made news for reducing coronavirus transmission in a late-stage study and ramping up its breast cancer pipeline with Regor’s CDK Inhibitors. Analysts upgraded Roche shares to Strong Buy, citing promising results of their obesity drug in early trials. Nevertheless,
Roche's shares have fallen 18% over the last three years, which is worrying for investors despite the upbeat momentum sparked by recent developments.
Roche Stocks News Analytics from Mon, 04 Dec 2023 08:00:00 GMT to Fri, 11 Oct 2024 14:08:40 GMT -
Rating -3
- Innovation 4
- Information 6
- Rumor -2
